Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Arsia, Eagle deal

    Eagle will acquire drug formulation and delivery company Arsia for $30 million, including $27.3 million in cash and $2.7 million in Eagle stock. Arsia is also eligible for up to $48 million in milestones.Arsia's …

    Published on 11/21/2016
  • Baylor, Cell Medica deal

    Baylor and Cell Medica expanded a June deal to include the development of an off-the-shelf allogeneic cell therapy using Baylors engineered invariant natural killer T (NKT) cells to treat graft-versus-host disease (GvHD…

    Published on 11/21/2016
  • Biodel, Albireo deal

    Albireo and Biodel merged to form Albireo Pharma Inc. (NASDAQ:ALBO, Boston, Mass.). The company plans to start a pivotal trial of lead compound A4250 next year to treat progressive familial intrahepatic cholestasis (…

    Published on 11/21/2016
  • Bristol-Myers, Johns Hopkins University deal

    Bristol-Myers Squibb and Johns Hopkins partnered to identify mechanisms of response and resistance to checkpoint inhibitors, including BMSs Opdivo nivolumab, Yervoy ipilimumab and other investigational products or …

    Published on 11/21/2016
  • EnBiotix, AMP deal

    EnBiotix acquired AMP Therapeutics for an undisclosed sum and formed subsidiary EnBiotix GmbH, which EnBiotix said will facilitate partnering and fundraising in Europe. AMP was developing a portfolio of antimicrobial …

    Published on 11/21/2016
  • Enterome, Bristol-Myers Squibb deal

    Bristol-Myers Squibb and Enterome partnered to discover and develop microbiome-associated biomarkers, targets, therapeutic molecules and companion diagnostics for cancer. The partners also plan to identify biomarkers …

    Published on 11/21/2016
  • Gilead, GlobeImmune deal

    GlobeImmune said Gilead terminated a 2011 deal granting Gilead rights to GS-4774. GlobeImmune regained all rights to the product. GS-4774, a Tarmogen comprising a heat-inactivated Saccharomyces cerevisiae that expresses…

    Published on 11/21/2016
  • LG Life Sciences, LG Chem deal

    In September, LG Corp. (KSE:003550, Seoul, South Korea) affiliates LG Life Sciences and LG Chem said they would merge in a stock deal, with the latter remaining as the surviving entity. The deal is expected to close on …

    Published on 11/21/2016
  • Oxford, Evotec deal

    The university and its research commercialization company Oxford University Innovation (OUI) and Oxford Sciences Innovation (OSI) IP investment fund partnered with Evotec for three years to form LAB282, a 13 million ($…

    Published on 11/21/2016
  • ReveraGen, Actelion deal

    Actelion and ReveraGen partnered to develop and commercialize vamorolone to treat Duchenne muscular dystrophy (DMD). Actelion has already paid $10 million in R&D expenses and will also provide up to $1 million per …

    Published on 11/21/2016
  • Sanofi, Alnylam deal

    Sanofis Sanofi Genzyme unit exercised an option under a 2014 deal to license exclusive rights to co-develop and co-commercialize fitusiran to treat hemophilia and other rare bleeding disorders in the U.S., Canada and …

    Published on 11/21/2016
  • SciClone deal

    SciClone received an unsolicited bid from a consortium led by ABM Management Ltd. and GL Capital Management GP Ltd. to acquire all outstanding shares not already owned for $11.18 per share in cash. The price is a 13.5% …

    Published on 11/21/2016
  • Scripps Research Institute, BlinkBio deal

    Scripps granted BlinkBio an option to exclusively license Dual Variable Domain-Fab (DVD-Fab) technology, which the biotech will use to develop Tunable Drug Conjugates (TDCs), initially to treat cancer. DVD-Fab consists …

    Published on 11/21/2016
  • Selecta, Sanofi deal

    Selecta said Sanofi terminated a 2012 deal to develop toleragenic antigen-specific immunotherapies against peanut allergy and celiac disease using Selecta's Synthetic Vaccine Particle (SVP) platform. Selecta said Sanofi…

    Published on 11/21/2016
  • Thar, Gruenenthal deal

    Grnenthal acquired drug formulation company Thar. Thar's Enhance technology is designed to convert IV drugs into oral candidates. Grnenthal plans to conduct Phase III testing of Thar's lead program, T121, to treat …

    Published on 11/21/2016
  • Virttu, Sorrento deal

    Sorrentos TNK Therapeutics Inc. subsidiary will acquire Virttu for $5 million in Sorrento stock at closing plus $20 million in TNK stock within 12 months after closing. The deal is expected to close next quarter.Virttu'…

    Published on 11/21/2016
  • AdAlta, XL-protein deal

    AdAlta and XL-protein partnered to develop and commercialize a long-acting version of AdAltas AD-114 to treat idiopathic pulmonary fibrosis (IPF). The partners will use XL-proteins PASylation technology to increase the …

    Published on 11/14/2016
  • Amgen, J&J deal

    Amgen and Johnson & Johnson's Janssen Biotech Inc. unit partnered to evaluate combinations of Amgen's Kyprolis carfilzomib and Janssens Darzalex daratumumab to treat multiple myeloma (MM) and other cancers. Amgen …

    Published on 11/14/2016
  • Amyris deal

    Amyris and an undisclosed company partnered to discover and develop a natural and natural-like compound library against an undisclosed target chosen by the partner. The companies will use Amyris uPharm technology, which…

    Published on 11/14/2016
  • Avacta, Memorial Sloan Kettering deal

    Avacta and Memorial Sloan partnered to evaluate Avactas Affimer technology in CAR T cell applications. Affimers are non-antibody scaffold proteins, which the company said may have advantages over antibody fragment …

    Published on 11/14/2016
  • Bellicum, Bambino Gesu Children's Hospital deal

    Bellicum and the hospital partnered to jointly develop CAR T cell and T cell receptor (TCR) therapies discovered by the hospital and engineered with Bellicums CaspaCIDe molecular safety switch technology. Bellicum will …

    Published on 11/14/2016
  • Bristol-Myers, Lexicon deal

    Lexicon said it gained full rights to develop and commercialize LX9211 (BMS-986176), a compound that was discovered by the companies as part of a 2003 deal. Lexicon expects the oral small molecule neuropathic pain …

    Published on 11/14/2016
  • Eli Lilly, Eddingpharm deal

    Eli Lilly granted Eddingpharm exclusive rights to promote and distribute antibiotics Ceclor cefaclor and Vancocin vancomycin in mainland China, effective Jan. 1, 2017. Lilly said the deal will enable it to focus …

    Published on 11/14/2016
  • Epizyme, NCI deal

    Epizyme entered into two cooperative research and development agreements (CRADAs) with NCI's Cancer Therapy Evaluation Program (CTEP) to evaluate tazemetostat and pinometostat from Epizyme to treat cancer. NCI will …

    Published on 11/14/2016
  • Genexine, Merck deal

    Genexine and Merck partnered to conduct a Phase Ib/IIa trial evaluating Genexine's GX-188E in combination with Merck's cancer drug Keytruda pembrolizumab to treat HPV-induced cancers. Genexine will conduct the study, …

    Published on 11/14/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993